Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Raloxifene (Evista) vs Taurine: Taurine has the stronger overall evidence (7.5 vs 5.3/10); they're alternatives for bone health — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Taurine wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Too few graded studies
Top outcomes
Verdict
Too few graded studies
2 of 2 studies with measurable effects showed benefit.
Top outcomes
Shared outcomes (1)
Outcomes where both Raloxifene (Evista) and Taurine have evidence — compare verdict strength side-by-side.
Approved (postmenopausal women) / off-label (male) — clinician-directed. For osteoporosis treatment/prevention and breast-cancer risk reduction the standard, validated dose is 60 mg once daily (the cited MORE and RUTH trials used 60 mg a day, and MORE also tested 120 mg a day: both doses reduced vertebral fracture risk, and the abstract does not compare side effects between them). For off-label male gynecomastia no cited study gives a dose, none covers men or children, and there is no FDA-approved male dose and the male evidence is thin and retrospective.
Any time of day
Raloxifene hydrochloride 60 mg tablets (approved for postmenopausal osteoporosis and breast-cancer risk reduction)
1-3g daily
Pre-workout for performance, Evening for sleep
Powder or capsules
Months to years
Years
Throughout use
Throughout use
4-8 weeks
8-12 weeks
2-4 weeks
Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.
JAMA (1999) · Rct · n=7705
MORE: multicenter, randomized, double-blind, placebo-controlled trial of raloxifene 60 or 120 mg/day in 7,705 postmenopausal women with osteoporosis, followed up to 36 months
The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.
JAMA (1999) · Rct · n=7705
Pre-specified breast-cancer analysis of the MORE RCT (7,705 postmenopausal women with osteoporosis), followed a median 40 months
Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.
J Natl Cancer Inst (2004) · Rct · n=5213
CORE: extension of the randomized MORE trial giving 4 additional years of raloxifene 60 mg/day (n=3,510) vs continued placebo (n=1,703)
Effects of Nutritional Supplements on Endurance Performance and Subjective Perception in Athletes Exercising in the Heat: A Systematic Review and Network Meta-Analysis
Nutrients (2025) · Meta analysis · n=552
Standardized mean differences (SMDs) and posterior probabilities (P-scores based on Bayesian ranking) were calculated using random-effects and Bayesian models.
Effect of a 12-mo intervention with whey protein powder on cognitive function in older adults with mild cognitive impairment: a randomized controlled trial
The American journal of clinical nutrition (2025) · Rct · n=107
The results also found a significant beneficial effect of the active intervention for several secondary cognitive outcomes such as Digit Symbol Substitution Test score, and the mean difference between groups in the ITT analysis was 2.72 (95% CI: 0.20, 5.23).
Caffeine and taurine: a systematic review and network meta-analysis of their individual and combined effects on physical capacity, cognitive function, and physiological markers
Journal of the International Society of Sports Nutrition (2025) · Meta analysis
Posterior estimates indicated that CAF+TAU was associated with a credible positive effect on anaerobic capacity (g = 0.46, 95% CrI [0.19, 0.71]) and reaction time (g = 0.75, 95% CrI [0.29, 1.18]) compared to CAF or TAU alone.
Rests on two meta-analyses that state the dose range they cover. One (PMID 29546641, 10 studies, single doses or up to 2 weeks of 1 to 6 g a day) found endurance improved (Hedges' g 0.40) and that the dose did not change the size of the effect. The other (PMID 40852891, 23 randomised trials of a single dose, 308 participants) found a small-to-moderate overall gain (g 0.25, I² 61%), no significant dose-response within 1 to 6 g, and rated the certainty low to very low. So the curve is flat from 1 g to 6 g. No minimum, optimal or ceiling dose is set, because neither abstract reports an effect or safety at a single dose within the range.
AI-estimated from published studies. Interpret as directional guidance.
Taurine has a higher evidence score (7.5/10 vs 5.3/10) and wins in 2 of 3 categories.
For bone health, Taurine has a higher relevance score (80 vs 76).
No documented interaction was found in the data searched. This does not establish that this exact combination is safe.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.